587
Views
0
CrossRef citations to date
0
Altmetric
Articles

Association between single nucleotide polymorphism of BRCA1-interacting protein C-terminal helicase 1 and early-onset breast cancer in Uygur and Han women in Xinjiang of China

ORCID Icon, & ORCID Icon
Pages 1750-1756 | Received 02 Apr 2019, Accepted 11 Aug 2019, Published online: 17 Dec 2019

References

  • Yang L, Ma B, Sun G, et al. Up-regulated expression of mammalian target of rapamycin in human epidermal growth factor receptor-2 over-expressing breast cancer. Chin J of Exp Surg. 2016;33:894–896.
  • Sun N, Sun G, Ma B. Differential expression of breast cancer susceptibility gene 1 mRNA and protein in sporadic breast cancer. Chin J of Exp Surg. 2016;33:884–887.
  • Zheng Y, Han N, Hou S, et al. The expression of DNA polymerase-β in breast cancer and its effect on migration of breast cancer cells. Chin J of Exp Surg. 2016;33:2135–2137.
  • Jia M, Guo J, Meng D. Advances of transcription factor Bach1 in cardiovascular diseases. J Shanghai Univ. 2016;22:326–330.
  • Kote-Jarai Z, Jugurnauth S, Mulholland S, et al. A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer. Br J Cancer. 2009;100:426–430.
  • Cantor SB, Bell DW, Ganesan S, et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 2001;105:149–160.
  • Yu X, Chini CC, He M, et al. The BRCT domain is a phospho-protein binding domain. Science. 2003;302:639–642.
  • Levitus M, Joenje H, de Winter JP. The Fanconi anemia pathway of genomic maintenance. Cell Oncol. 2006;28:3–29.
  • Catucci I, Milgrom R, Kushnir A, et al. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Fam Cancer. 2012;11:483–491.
  • Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38:1239–1241.
  • Cizmarikova M, Wagnerova M, Schonova L, et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 2010;10:62–69.
  • Cantor S, Drapkin R, Zhang F, et al. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci USA. 2004;101:2357–2362.
  • Cantor SB, Guillemette S. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. Future Oncol. 2011;7:253–261.
  • Shi J, Tong J, Cai S, et al. Correlation of the BACH1 Pro919Ser polymorphism with breast cancer risk: A literature-based meta-analysis and meta-regression analysis. Exp Ther Med. 2013;6:435–444.
  • Ren LP, Xian YS, Diao DM, et al. Further evidence for the contribution of the BRCA1-interacting protein-terminal helicase 1 (BRIP1) gene in breast cancer susceptibility. Genet Mol Res. 2013;12:5793–5801.
  • Pabalan N, Jarjanazi H, Ozcelik H. Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2013;137:553–558.
  • Cao AY, Huang J, Hu Z, et al. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat. 2009;115:51–55.
  • Luo L, Lei H, Du Q, et al. No mutations in the BACH1 gene in BRCA1 and BRCA2 negative breast-cancer families linked to 17q22. Int J Cancer. 2002;98:638–639.